Abstract: A system for capturing a 3D image of a subject includes a detection device which is structured to capture images of the subject and surrounding environment, a projection device which is structured to provide a source of structured light, and a processing unit in communication with the detection device and the projection device. The processing unit is programmed to: analyze an image of the subject captured by the detection device; modify one or more of: the output of the projection device or the intensity of a source of environmental lighting illuminating the subject based on the analysis of the image; and capture a 3D image of the subject with the detection device and the projection device using the modified one or more of the output of the projection device or the intensity of the source of environmental lighting illuminating the subject.

Abstract: The present disclosure is for an inverted diffuser usable in wellheads and other wellsite equipment. The inverted diffuser includes at least one first section having a first vertical inner surface, a first inclined inner surface relative to the first vertical inner surface, and one or more channels supporting one or more releasable fasteners between the at least one first section and a wall of a wellhead or of a wellsite equipment. At least one second section is press-fitted or fastened adjacent to the at least one first section. A method for application of the inverted diffuser in a wellhead and in other wellsite equipment is also disclosed, along with a method of manufacture of the inverted diffuser.

Abstract: The present disclosure provides for processes and systems for the purification of alkyl sulfide product streams including dimethyl sulfide (DMS). In some aspects, the disclosure provides for the removal of carbon disulfide (CS2) from DMS via hydrolytic catalysis. In further embodiments, the disclosed catalytic processes are performed using mixed-metal catalyst systems such as cobalt-molybdenum (CoMo) and nickel-molybdenum (NiMo) catalyst systems.

Abstract: The present disclosure is for an inverted diffuser usable in wellheads and other wellsite equipment. The inverted diffuser includes at least one first section having a first vertical inner surface, a first inclined inner surface relative to the first vertical inner surface, and one or more channels supporting one or more releasable fasteners between the at least one first section and a wall of a wellhead or of a wellsite equipment. At least one second section is press-fitted or fastened adjacent to the at least one first section. A method for application of the inverted diffuser in a wellhead and in other wellsite equipment is also disclosed, along with a method of manufacture of the inverted diffuser.

Abstract: The disclosure provides methods of treating cancer in a subject or preventing a relapse or reducing the incidence of relapse of cancer in a subject in remission, comprising administering to the subject: (a) a therapeutically effective amount of an immunotherapeutic agent, e.g., an immune checkpoint blockade therapy, an adoptive cellular therapy, a marrow-infiltrating lymphocytes, an adenosine A2aR inhibitor, or an antibody; and (b) a compound having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON).

Abstract: Compositions of dendrimers conjugated with one or more therapeutic agents that decrease exosome secretion and methods of use thereof for treating, alleviating, and/or preventing one or more symptoms associated with one or more neurological disease or disorders, cancer, inflammatory diseases, bacterial and viral infections, and other disorders have been developed. Preferably, the therapeutic agents are one or more agents that inhibit or reduce activity and/or quantity of neutral sphingomyelinase 2 (nSMase2) such as small molecule inhibitors of nSMase2. Compositions are particularly suited for reducing A? plaque formation, reducing tau propagation, improving cognition, or combinations thereof in a subject with psychiatric and neurological disorders. Compositions are also suited for treating, alleviating, and/or preventing one or more symptoms associated with cancer, bacterial and viral infections, and inflammatory diseases.

Abstract: An innovative modular indoor growing system uses a holistic approach that includes an heirloom/ancestral seed collection sourced from global seed banks, an in-home easy-to-use production system, passport-style information for people to explore or experience the global seed diversity of a crop, onboard sensors and cameras for real-time monitoring of the crop, virtual assistance facilitating the selection, development, and creation of new varieties, and a crowd sourced data collection network that relies on artificial intelligence to build a state-of-the-art knowledge base for product optimization and consumer intelligence.

Abstract: The use of carboxylate ligand modified ferric iron hydroxide compositions for the treatment or prevention of iron deficiency associated with liver diseases is disclosed, and more particularly to the class of Iron Hydroxide Adipate Tartrate (IHAT) materials for 10 use in the treatment or prevention of iron deficiency associated with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).

Abstract: Liquid dressing compositions liquid for veterinary use in the treatment or prevention of infection and/or wounds are described that comprise shellac, an anti-infective metal active and a solvent. The compositions are capable of forming a barrier when topically applied to a non-human animal subject, providing an easily applied barrier for protecting lesions and other wounds from external infective agents in a veterinary setting.

Abstract: Liquid dressing compositions liquid for use in the treatment or prevention of infection and/or wounds are described that comprise shellac, an anti-infective metal active and a solvent. The compositions are capable of forming a barrier when topically applied to a subject, providing an easily applied barrier for protecting lesions and other wounds from external infective agents.

Abstract: The present disclosure is for an inverted diffuser usable in wellheads and other wellsite equipment. The inverted diffuser includes at least one first section having a first vertical inner surface, a first inclined inner surface relative to the first vertical inner surface, and one or more channels supporting one or more releasable fasteners between the at least one first section and a wall of a wellhead or of a wellsite equipment. At least one second section is press-fitted or fastened adjacent to the at least one first section. A method for application of the inverted diffuser in a wellhead and in other wellsite equipment is also disclosed, along with a method of manufacture of the inverted diffuser.

Abstract: The present disclosure is for an inverted diffuser usable in wellheads and other wellsite equipment. The inverted diffuser includes at least one first section having a first vertical inner surface, a first inclined inner surface relative to the first vertical inner surface, and one or more channels supporting one or more releasable fasteners between the at least one first section and a wall of a wellhead or of a wellsite equipment. At least one second section is press-fitted or fastened adjacent to the at least one first section. A method for application of the inverted diffuser in a wellhead and in other wellsite equipment is also disclosed, along with a method of manufacture of the inverted diffuser.

Abstract: The present disclosure is for an inverted diffuser usable in wellheads and other wellsite equipment. The inverted diffuser includes at least one first section having a first vertical inner surface, a first inclined inner surface relative to the first vertical inner surface, and one or more channels supporting one or more releasable fasteners between the at least one first section and a wall of a wellhead or of a wellsite equipment. At least one second section is press-fitted or fastened adjacent to the at least one first section. A method for application of the inverted diffuser in a wellhead and in other wellsite equipment is also disclosed, along with a method of manufacture of the inverted diffuser.

Abstract: Combinations of anti-cancer antibodies and inhibitory antibodies to CD223 overcome immune suppression in cancer patients. The inhibitory antibodies may be generated in an animal by injection of fragments of CD223. Antibodies may be monoclonal antibodies or single chain antibodies or humanized antibodies.

Abstract: The disclosure provides methods of treating cancer in a subject or preventing a relapse or reducing the incidence of relapse of cancer in a subject in remission, comprising administering to the subject: (a) a therapeutically effective amount of an immunotherapeutic agent, e.g., an immune checkpoint blockade therapy, an adoptive cellular therapy, a marrow-infiltrating lymphocytes, an adenosine A2aR inhibitor, or an antibody; and (b) a compound having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON).

Abstract: Combinations of anti-cancer antibodies and inhibitory antibodies to CD223 overcome immune suppression in cancer patients. The inhibitory antibodies may be generated in an animal by injection of fragments of CD223. Antibodies may be monoclonal antibodies or single chain antibodies or humanized antibodies.

Abstract: The disclosure provides methods of treating cancer in a subject or preventing a relapse or reducing the incidence of relapse of cancer in a subject in remission, comprising administering to the subject: (a) a therapeutically effective amount of an immunotherapeutic agent, e.g., an immune checkpoint blockade therapy, an adoptive cellular therapy, a marrow-infiltrating lymphocytes, an adenosine A2aR inhibitor, or an antibody; and (b) a compound having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON).

Abstract: Anti-CD223 antibodies overcome immune suppression in cancer patients. The anti-CD223 antibodies may be generated in an animal by injection of fragments of CD223. Antibodies may be monoclonal antibodies or single chain antibodies or humanized antibodies.

Abstract: Embodiments of the present disclosure include a method of replacing valve operation methods during fracturing operations including installing a first operator on a first valve of a first fracturing tree. The method also includes installing a second operator on a second valve of a second fracturing tree, the second fracturing tree being adjacent the first fracturing tree. The method also includes removing the first operator from the first valve, the first valve maintaining a position on the first fracturing tree after the first operator is removed. The method further includes removing the second operator from the second valve, the second valve maintaining a position on the second fracturing tree after the second operator is removed. The method also includes installing the first operator on the second valve after the first operator is removed from the first valve and after the second operator is removed from the second valve.

Abstract: The disclosure provides methods of treating a condition, disease, or disorder in a subject that involves metabolically reprogrammed cells whose activation, function, growth, proliferation, or survival depends on increased activity of at least one metabolic pathway selected from the group consisting of glutamine metabolism, glycolysis, and fatty acid synthesis, comprising administering to the subject a compound having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON).